| Literature DB >> 28639538 |
Yogita Rochlani1, Naga Venkata Pothineni2, Swathi Kovelamudi3, Jawahar L Mehta3.
Abstract
Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities that include hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia, and is strongly associated with an increased risk for developing diabetes and atherosclerotic and nonatherosclerotic cardiovascular disease (CVD). The pathogenesis of MetS involves both genetic and acquired factors that contribute to the final pathway of inflammation that leads to CVD. MetS has gained significant importance recently due to the exponential increase in obesity worldwide. Early diagnosis is important in order to employ lifestyle and risk factor modification. Here, we review the epidemiology and pathogenesis of MetS, the role of inflammation in MetS, and summarize existing natural therapies for MetS.Entities:
Keywords: atherogenic dyslipidemia; cardiovascular disease; hypertension; insulin resistance; metabolic syndrome; nutraceuticals; obesity
Mesh:
Substances:
Year: 2017 PMID: 28639538 PMCID: PMC5933580 DOI: 10.1177/1753944717711379
Source DB: PubMed Journal: Ther Adv Cardiovasc Dis ISSN: 1753-9447